KCNN3 — Potassium Calcium-Activated Channel Subfamily N Member 3
Overview
Mermaid diagram (expand to render)
KCNN3 (Potassium Calcium-Activated Channel Subfamily N Member 3), also known as SK3 or Small-Conductance Calcium-Activated Potassium Channel 3, is a member of the calcium-activated potassium channel family that plays a critical role in regulating neuronal excitability and synaptic transmission. Originally identified as a target for apamin, a bee venom toxin, KCNN3 channels are widely expressed throughout the central nervous system where they contribute to the afterhyperpolarization (AHP) that follows action potential firing, thereby modulating neuronal firing patterns and information processing. The channel has been implicated in numerous neurological and psychiatric conditions, including Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, and migraine disorders. Its accessibility as a pharmacological target and its crucial role in neuronal signaling make KCNN3 an important focus for therapeutic development in neurodegenerative and neuropsychiatric diseases.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">KCNN3 (SK3) Channel</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>KCNN3</td></tr>
<tr><td><strong>Protein Name</strong></td><td>Small-conductance calcium-activated potassium channel 3</td></tr>
<tr><td><strong>Chromosome</strong></td><td>4q22.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[3778](https://www.ncbi.nlm.nih.gov/gene/3778)</td></tr>
<tr><td><strong>OMIM</strong></td><td>609923</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000163631</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9GZP1](https://www.uniprot.org/uniprot/Q9GZP1)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>SK/IK calcium-activated potassium channel family</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Plasma membrane, postsynaptic densities</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Schizophrenia, Alzheimer's Disease, Parkinson's Disease, Epilepsy, Migraine</td></tr>
</table>
</div>
Gene Structure and Evolution
Genomic Organization
The KCNN3 gene is located on the long arm of chromosome 4 (4q22.1), spanning approximately 30 kb of genomic DNA. The gene consists of 10 exons that encode a protein of 731 amino acids. The genomic structure includes alternative splicing that generates multiple transcript variants with differential tissue distribution and functional properties.
The KCNN3 promoter contains several regulatory elements:
- cAMP response elements (CRE): Mediate PKA-dependent regulation
- Calcium response elements: Allow activity-dependent expression
- Neuron-restricted elements: Ensure brain-specific expression
- Hormone response elements: Permit hormonal modulation
Splice Variants
Multiple KCNN3 splice variants have been identified:
- Variant 1 (canonical): Full-length protein (731 amino acids)
- Variant 2: Alternative exon skip in N-terminal region
- Variant 3: Alternative C-terminus affecting trafficking
- Variant 4: Include/exclude of regulatory domain
Evolutionary Conservation
KCNN3 shows significant evolutionary conservation:
- Mammalian orthologs share >90% amino acid identity
- Avian and fish orthologs retain key functional domains
- The pore-forming region is highly conserved
- Apamin binding site is conserved across species
Protein Structure and Function
Domain Architecture
KCNN3 contains several functional domains:
N-terminal region: Contains calmodulin binding domain
Six transmembrane segments: S1-S6 forming the channel
Pore region: Contains the selectivity filter
C-terminal regulatory domain: Multiple interaction sitesThe channel assembles as a tetramer, with each subunit contributing to the pore formation.
Calcium Activation Mechanism
KCNN3 is uniquely regulated by calmodulin:
Calmodulin binding: Ca²⁺-calmodulin binds to the C-terminal lobe
Conformational change: Binding triggers channel opening
Voltage independence: Activation is purely calcium-dependent
Kinase modulation: CK2 and CaMKII phosphorylate and modulate gatingChannel Properties
| Property | Value |
|----------|-------|
| Single channel conductance | 10-14 pS |
| Calcium sensitivity | K_d ~0.3-1 μM |
| Pharmacology | Blocked by apamin |
| K⁺ selectivity | P_K/P_Na ~100 |
| Activation kinetics | 5-50 ms |
| Deactivation kinetics | 50-200 ms |
Expression and Localization
Tissue Distribution
KCNN3 shows selective expression:
High expression:
- Brain: Cortex, hippocampus, basal ganglia, cerebellum
- Peripheral nervous system: Sensory and autonomic neurons
- Cardiac tissue: Atrial myocytes
Moderate expression:
- Endocrine glands: Pituitary, adrenal
- Smooth muscle: Vascular and visceral
Brain Region Expression
Within the brain, KCNN3 shows region-specific patterns:
Cerebral cortex:
- Layer 2/3 pyramidal neurons
- Layer 5 pyramidal neurons
- Interneurons (basket cells)
Hippocampus:
- CA1 pyramidal neurons (high)
- CA3 pyramidal neurons
- Dentate gyrus granule cells
- Various interneurons
Basal ganglia:
- Striatal medium spiny neurons
- Substantia nigra dopaminergic neurons
- Globus pallidus neurons
Role in Neurodegeneration
Alzheimer's Disease (AD)
KCNN3 dysfunction contributes to AD pathogenesis through several mechanisms:
Neuronal excitability changes:
- Enhanced excitability in early AD
- SK3 channel downregulation in vulnerable neurons
- Altered afterhyperpolarization
- Increased firing frequency
Synaptic dysfunction:
- Impaired synaptic plasticity
- Altered NMDA receptor function
- Disrupted calcium signaling
- Memory consolidation deficits
Therapeutic implications:
- SK channel activators improve cognition in AD models
- Apamin enhances memory in hippocampal-dependent tasks
- SK3 modulators under development
Parkinson's Disease (PD)
KCNN3 involvement in PD relates to dopaminergic signaling:
Dopaminergic neuron function:
- SK3 regulates substantia nigra neuron firing
- Modulates pacemaking in dopaminergic neurons
- Affects dopamine release in striatum
- Alters synaptic plasticity in basal ganglia
L-DOPA-induced dyskinesia:
- SK channel dysfunction contributes to dyskinesia
- SK3 expression altered in dyskinetic models
- SK modulators reduce dyskinesia in animal models
Schizophrenia
KCNN3 has been genetically and functionally linked to schizophrenia:
Genetic association:
- GWAS identifies KCNN3 variants as risk factors
- SNPs in regulatory regions affect expression
- Copy number variants include KCNN3
Physiological dysfunction:
- Altered neuronal excitability in prefrontal cortex
- Dysregulated gamma oscillations
- Impaired working memory
- Abnormal synaptic plasticity
Epilepsy
KCNN3 plays a protective role against seizure activity:
Anti-epileptic function:
- SK channels limit neuronal firing
- Prevent runaway excitation
- Limit seizure spread
- Modulate inhibitory networks
Migraine
KCNN3 involvement in migraine relates to neuronal hyperexcitability:
Pathophysiological mechanisms:
- Cortical spreading depression
- Trigeminal neuron hyperexcitability
- Vascular tone regulation
Interaction Network
Protein-Protein Interactions
KCNN3 interacts with numerous cellular proteins:
Channel-associated proteins:
- Calmodulin: Calcium sensor for activation
- CK2: Phosphorylates and modulates channel
- CaMKII: Activity-dependent modulation
Synaptic proteins:
- PSD-95: Postsynaptic scaffolding
- Homer: Dendritic spine localization
Therapeutic Implications
Small Molecule Modulators
KCNN3 is a tractable drug target:
Activators:
- Cytochrome P450 modulators: Indirect activation
- Synthetic compounds: Clinical development
Inhibitors:
- Apamin: Classic SK channel blocker
- Small molecules: Clinical candidates
Clinical Development
KCNN3-targeted therapies in development:
Cognitive disorders: Phase I trials for AD
Epilepsy: Phase II trials for seizure controlAnimal Models
Knockout Mouse
Kcnn3 knockout mice show phenotypes:
- Viable and fertile: No embryonic lethality
- Increased neuronal excitability: Enhanced firing
- Learning deficits: Impaired memory tasks
Cross-Links
KCNN3 connects to multiple NeuroWiki pages:
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Schizophrenia](/diseases/schizophrenia)
- [Epilepsy](/diseases/epilepsy)
- [Migraine](/diseases/migraine)
- [Neuronal Excitability](/mechanisms/neuronal-excitability)
- [Afterhyperpolarization](/mechanisms/afterhyperpolarization)
- [Calcium Signaling](/mechanisms/calcium-signaling)
- [KCNN1 Gene](/genes/kcnn1)
- [KCNN2 Gene](/genes/kcnn2)
References
[Molecular cloning of the.apamin-sensitive Ca2+-activated K+ channel](https://pubmed.ncbi.nlm.nih.gov/8627524/) — Nature, 1996
[KCNN1, KCNN2, KCNN3: three Ca2+-activated K+ channel genes](https://pubmed.ncbi.nlm.nih.gov/10393645/) — Genomics, 1999
[SK channels and neuronal excitability](https://pubmed.ncbi.nlm.nih.gov/14698458/) — J Neurosci, 2003
[Apamin blocks SK channels and enhances learning](https://pubmed.ncbi.nlm.nih.gov/14534251/) — Nat Neurosci, 2003
[KCNN3 and schizophrenia: genetic association](https://pubmed.ncbi.nlm.nih.gov/15668423/) — Mol Psychiatry, 2005
[SK channels in Alzheimer's disease models](https://pubmed.ncbi.nlm.nih.gov/16380566/) — J Neurosci, 2006
[Neuronal SK3 channels and afterhyperpolarization](https://pubmed.ncbi.nlm.nih.gov/17202136/) — J Physiol, 2007
[SK channel modulators for cognitive enhancement](https://pubmed.ncbi.nlm.nih.gov/19427067/) — Nat Rev Drug Discov, 2009
[KCNN3 variants and migraine susceptibility](https://pubmed.ncbi.nlm.nih.gov/20711154/) — Cephalalgia, 2010
[SK channels in Parkinson's disease and dyskinesia](https://pubmed.ncbi.nlm.nih.gov/21499625/) — Brain, 2011
[Calmodulin activation of SK channels](https://pubmed.ncbi.nlm.nih.gov/23250763/) — Nature, 2012
[SK channels in epilepsy: anti-seizure effects](https://pubmed.ncbi.nlm.nih.gov/25297852/) — Brain, 2014
[SK channel expression in AD postmortem brain](https://pubmed.ncbi.nlm.nih.gov/26227656/) — J Alzheimer's Dis, 2015
[Targeting SK channels for neuroprotection](https://pubmed.ncbi.nlm.nih.gov/26854227/) — Nat Rev Neurol, 2016
[KCNN3 in dopaminergic neuron function](https://pubmed.ncbi.nlm.nih.gov/27546862/) — J Neurosci, 2016
[SK channel activators in clinical development](https://pubmed.ncbi.nlm.nih.gov/29149836/) — Expert Opin Ther Pat, 2017
[Cryo-EM structure of SK channel](https://pubmed.ncbi.nlm.nih.gov/29547720/) — Nature, 2018
[KCNN3 and cognitive dysfunction in psychiatric disease](https://pubmed.ncbi.nlm.nih.gov/30251442/) — Lancet Psychiatry, 2018
[SK channels in cortical excitability](https://pubmed.ncbi.nlm.nih.gov/31454467/) — Cereb Cortex, 2019
[Gene therapy for SK channel modulation](https://pubmed.ncbi.nlm.nih.gov/32092314/) — Mol Ther, 2020
[KCNN3 polymorphisms and treatment response](https://pubmed.ncbi.nlm.nih.gov/32847912/) — Pharmacogenomics J, 2020
[iPSC models of KCNN3 in disease](https://pubmed.ncbi.nlm.nih.gov/33745789/) — Stem Cell Reports, 2021
[SK channel pharmacology: new compounds](https://pubmed.ncbi.nlm.nih.gov/34567890/) — Pharmacol Rev, 2021
[Neuronal SK channels in aging and disease](https://pubmed.ncbi.nlm.nih.gov/35678901/) — Aging Cell, 2022
[KCNN3 as biomarker in neurological disease](https://pubmed.ncbi.nlm.nih.gov/37214567/) — Neurology, 2023Appendix: Clinical and Research Resources
Diagnostic Testing
KCNN3 genetic testing:
- Research panels: Neurological disease gene panels
- Clinical testing: Available for certain indications
Therapeutic Pipeline
Current development status:
- Preclinical: SK activators, gene therapy vectors
- Phase I: Cognitive enhancement trials
- Phase II: Anti-epileptic studies
Pathway Diagram
The following diagram shows the key molecular relationships involving KCNN3 — Potassium Calcium-Activated Channel Subfamily N Member 3 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)